Juvent: Clinical Trial Confirms New Device Improves Bone Density in Cancer Survivors

11% Increase in Bone Density in Study Published in the Journal of the American Medical Association (JAMA) Oncology

The Juvent Micro-Impact Platform
The Juvent Micro-Impact Platform

Regenerative Technologies Corporation

April 20, 2016

RIVIERA BEACH, FL–(Marketwired – April 20, 2016) – Juvent (www.juvent.com), a leader in orthopedic regenerative therapies for bone and musculoskeletal health, announced today very positive results from the St. Jude Children’s Hospital Clinical Trial. Kirsten K. Ness, PT, Ph.D., Principal Investigator, states, “The first goal of treating low BMD (bone mineral density) in childhood cancer survivors is to manage potential underlying causes including endocrine disorders and nutritional deficiencies. In our study using LMS (Juvent® Dynamic Motion Therapy Platform), we managed endocrine problems and supplemented everyone on the study. Our randomized study was effective in improving total body and tibial BMD in children randomized to the device while children in the placebo group had decreases in BMD. Importantly, we had no adverse events with a year of twice daily 10 minute sessions. This portable device is safe and effective as an intervention for childhood cancer survivors who have low BMD and whose endocrine and nutrition status is well managed.”
Gunnar Andersson, M.D., Ph.D., Chairman Emeritus of Orthopaedic Surgery at Rush Presbyterian, past President of the Orthopaedic Research Society and Juvent Science Advisory Board (SAB) Member, stated, “This is a very important study with a spectacular result from a short period, non-invasive intervention that has no side effects.”
Richard Treharne, Ph.D., a leading FDA regulatory expert and SAB Member, said, “Randomized studies of orthopaedic devices are rare; with double-blind studies with placebo controls even rarer. To find any therapy that can increase total body bone mineral density is even more rare. The results from this study using a challenging patient population are striking, most encouraging, and warrant further study.”
“This is our first cancer patient study. Our other successful pediatric bone studies improved bone density with Cerebral Palsy, Thalassemia and Scoliosis patient populations. We believe this study creates a new standard of care and will move this important technology into children’s hospitals and pediatric clinics to help the over 300,000 pediatric cancer survivors1 who suffer from post-chemotherapy bone and joint damage. It also demonstrates the potential that this device could help the 14 million adult cancer survivors1 who struggle with similar problems. We plan to submit this data to the FDA to secure a clearance for this new indication,” says company Chairman & CEO, Rush Simonson.
David Brumfield, a leading biomechanical engineer and SAB Member, said, “Juvent’s platform offers an easy means of applying a proprietary, low-magnitude mechanical stimulation (LMMS; 0.3 g) calibrated to one’s own unique resonant frequency within a safe 32-37Hz range. As such, its use is more effective and safer than whole body vibration (WBV) devices which produce much larger magnitudes & frequencies with their associated side effects. This well-conducted study demonstrates that the safe and effective Juvent technology helped restore musculoskeletal health in these patients whose bone strength has been impaired by cancer treatments, thus improving the medical welfare of these who have already endured so much.”
“An 11% improvement in tibial BMD with no adverse events is a ‘home run’ by any criteria,” said Peter Simonson, a leading medical device developer, Georgia Tech mechanical engineer and Juvent President. “This study is another confirmation that the years of development of our patented software and mechanism was worth it. The software’s ability to automatically adapt to a user’s unique body mass and composition is the key,” said Simonson.  [see full press release]

Click here to learn more about Juvent from Suncoast Healthy Life

Advertisements